Clinical Trials Logo

Renal Replacement Therapy clinical trials

View clinical trials related to Renal Replacement Therapy.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05788211 Completed - Cardiogenic Shock Clinical Trials

REnal reCOVery After ECMO for Cardiogenic Shock (RECOVECMO)

RECOVECMO
Start date: January 1, 2022
Phase:
Study type: Observational

This retrospective study assesses long term renal outcome in patients having suffered medical or post cardiotomy refractory cardiogenic shock requiring renal replacement therapy (RRT) concomitant with veno-arterial extracorporeal membrane oxygenation (VA-ECMO). The authors seek to establish for accurate definition of renal recovery status predicting poor long-term renal outcomes.

NCT ID: NCT04977687 Completed - Acute Kidney Injury Clinical Trials

Machine Learning Predict Renal Replacement Therapy After Cardiac Surgery

Start date: September 1, 2020
Phase:
Study type: Observational

Cardiac surgery-associated acute kidney injury (CSA-AKI) is a major complication which may result in adverse impact on short- and long-term mortality. The researcher here developed several prediction models based on machine learning technique to allow early identification of patients who at the high risk of unfavorable kidney outcomes. The retrospective study comprised 2108 consecutive patients who underwent cardiac surgery from January 2017 to December 2020.

NCT ID: NCT04512131 Completed - Clinical trials for Renal Replacement Therapy

Impact of Dialysis Modality on Coagulation and Platelet Function

Start date: August 4, 2020
Phase:
Study type: Observational [Patient Registry]

The investigators will evaluate the impact of dialysis modality (intermittent hemodialysis or continuous renal replacement therapy) in coagulation and platelet function in critically ill patients

NCT ID: NCT04393428 Completed - COVID-19 Clinical Trials

Urinary Biomarkers for AKI Diagnosis in Patients With SARS-CoV-2 (COVID-19)

COVID-AKI
Start date: March 1, 2020
Phase:
Study type: Observational

Among patients with SARS-CoV-2 pneumonia, approximately 20% have an acute kidney injury (AKI) and 5% require renal replacement therapy. Occurrence of AKI in patients with COVID-19 is associated with increased morbidity and mortality. Early detection of patients at risk of AKI would allow to prevent onset or worsening of AKI. The aim of this study is to determine if urine biomarkers of renal tubular damage such as TIMP-2 and IGFBP7 could early identify patients with SARS-CoV-2 pneumonia at risk of developing AKI.

NCT ID: NCT04292210 Completed - Renal Failure Clinical Trials

Human Factors Validation Testing for the Peripal System; a Manual Connection Assist Device for Peritoneal Dialysis Devices

Start date: February 19, 2018
Phase: N/A
Study type: Interventional

It is estimated that there are currently over 3 million patients receiving dialysis treatment worldwide. With effective pre-dialysis counselling, a majority of patients choose the home-based therapy peritoneal dialysis (PD) but only approximately 11% of prevalent dialysis patients use this modality. Connection-assist devices can overcome the challenges posed by decreased manual dexterity and/or visual acuity, and can allow more patients to be treated with home-based therapies. As part of the CE marking authorization, a connection device has been evaluated for safety and ease of use in a usability study.

NCT ID: NCT04203784 Completed - Sepsis Clinical Trials

Meropenem and Piperacillin Plasma Concentrations During CRRT

ABC2
Start date: November 1, 2012
Phase:
Study type: Observational

This observational study reports meropenem and piperacillin plasma concentrations in patients treated with either antibiotic and simultaneous continuous renal replacement therapy (CRRT).

NCT ID: NCT04071171 Completed - Acute Kidney Injury Clinical Trials

Comparison of Biphozyl® and Phoxilium® as a Replacement Fluid During CVVH for AKI in Adults and Their Effects on pH-, Bicarbonate-levels and Respiratory Situation

Start date: August 1, 2020
Phase: Phase 2
Study type: Interventional

The primary objectives of the BiPhox-Trial are to demonstrate, that the use of Biphozyl® as a replacement fluid in adult critically ill acute kidney injury (AKI) patients, results in a lower rate of pH excursions and of bicarbonate (HCO3-) excursions compared to the use of Phoxilium® during the studied continuous veno-venous hemofiltration (CVVH) interval with regional citrate anticoagulation (RCA). The secondary objectives of the BiPhox-Trial are to evaluate the time to pH level normalization and the HCO3- substitution rates after initiation of CVVH treatment. Further, to demonstrate that the use of Biphozyl® as a replacement fluid in adult critically ill AKI patients, results in a more stable acid-base-status as well as improved respiratory situation due to lower intracorporeal HCO3- and carbon dioxide levels compared to the use of Phoxilium® during the studied CVVH interval with RCA.

NCT ID: NCT03836742 Completed - Acute Kidney Injury Clinical Trials

HEmoFiltration With Citric Acid Anticoagulation

HEFCAA
Start date: August 11, 2015
Phase:
Study type: Observational

Prospective observational study of all consecutive cardio-vascular surgical patients treated with post-dilution hemofiltration with regional citrate anticoagulation as first-choice anticoagulation method. The filter life-span was assessed in the context of postoperative cardiac surgical antithrombotic prophylaxis. Reasons for termination of hemofiltration sessions were assessed. The second aim of this study was to assess the influence ACD-A based anticoagulation protocol on acid-base and ion homeostasis in cardiac surgical patients with acute renal failure.

NCT ID: NCT03665311 Completed - Acute Kidney Injury Clinical Trials

Saline Versus Albumin Fluid for Extracorporeal Removal With Slow Low Efficiency Dialysis Feasibility Study

SAFER-SLED
Start date: March 25, 2019
Phase: Phase 2
Study type: Interventional

Objective: The primary aim of this 60 patient feasibility trial is to determine if, for critically ill patients treated with SLED for AKI, randomization to receive albumin (25%) boluses versus normal saline placebo boluses is feasible, with respect to the recruitment rate, blinding and adherence to the protocol.

NCT ID: NCT02718261 Completed - Critical Illness Clinical Trials

Sup-Icu RENal (SIREN)

SIREN
Start date: February 2016
Phase: Phase 4
Study type: Interventional

Data show that episodes of bleeding may often be observed in critically ill patients with dialysis-dependent acute renal failure (ARF) on renal replacement therapy (RRT). From a clinical perspective, patients with dialysis-dependent ARF and end-stage renal disease (ESRD) may be considered a high risk population in regard to e.g. development of gastrointestinal (GI-) bleeding. In the current prospective subanalysis "SIREN" of the randomized placebo-controlled clinical trial "SUP-ICU" (NCT02467621), the investigators seek to elucidate whether the subpopulation of critically ill patients with acute kidney injury requiring renal replacement therapy (RRT) benefit from prophylactic treatment with a proton-pump-inhibitor such as pantoprazole.